DK2744826T3 - Kombinationsterapi med et anti-cd19-antistof og en purin-analog - Google Patents
Kombinationsterapi med et anti-cd19-antistof og en purin-analog Download PDFInfo
- Publication number
- DK2744826T3 DK2744826T3 DK12745883.4T DK12745883T DK2744826T3 DK 2744826 T3 DK2744826 T3 DK 2744826T3 DK 12745883 T DK12745883 T DK 12745883T DK 2744826 T3 DK2744826 T3 DK 2744826T3
- Authority
- DK
- Denmark
- Prior art keywords
- purin
- antibody
- analog
- combination therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523862P | 2011-08-16 | 2011-08-16 | |
| EP11177660 | 2011-08-16 | ||
| PCT/EP2012/065904 WO2013024095A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a purine analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2744826T3 true DK2744826T3 (da) | 2022-03-28 |
Family
ID=47714800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12745883.4T DK2744826T3 (da) | 2011-08-16 | 2012-08-14 | Kombinationsterapi med et anti-cd19-antistof og en purin-analog |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20140227277A1 (enExample) |
| EP (2) | EP4083071A3 (enExample) |
| JP (1) | JP6114273B2 (enExample) |
| KR (3) | KR102117202B1 (enExample) |
| CN (1) | CN103703027B (enExample) |
| AU (1) | AU2012296905B2 (enExample) |
| BR (1) | BR112013033916B1 (enExample) |
| CA (1) | CA2841738C (enExample) |
| CY (1) | CY1125148T1 (enExample) |
| DK (1) | DK2744826T3 (enExample) |
| ES (1) | ES2909720T3 (enExample) |
| HR (1) | HRP20220224T1 (enExample) |
| HU (1) | HUE058855T2 (enExample) |
| IL (1) | IL230295B (enExample) |
| LT (1) | LT2744826T (enExample) |
| MX (1) | MX353589B (enExample) |
| PL (1) | PL2744826T3 (enExample) |
| PT (1) | PT2744826T (enExample) |
| RS (1) | RS63121B1 (enExample) |
| RU (1) | RU2664462C9 (enExample) |
| SG (1) | SG10201606788VA (enExample) |
| SI (1) | SI2744826T1 (enExample) |
| SM (1) | SMT202200160T1 (enExample) |
| WO (1) | WO2013024095A1 (enExample) |
| ZA (1) | ZA201401835B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
| IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
| EP3157553A4 (en) * | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| EP3603672B1 (en) * | 2015-05-26 | 2026-04-22 | Incyte Corporation | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| MX392561B (es) * | 2015-08-21 | 2025-03-24 | Morphosys Ag | Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda. |
| CN115932265B (zh) * | 2016-05-30 | 2026-04-14 | 因塞特公司 | 预测cd19抗体治疗在患者中的治疗益处的方法 |
| KR20230028571A (ko) | 2016-10-28 | 2023-02-28 | 모르포시스 아게 | 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 |
| IL297461B2 (en) * | 2017-05-31 | 2024-09-01 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| EP3652206A1 (en) | 2017-07-10 | 2020-05-20 | International-Drug-Development-Biotech | Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| CN119013293A (zh) * | 2021-12-22 | 2024-11-22 | 因赛特公司 | 抗cd19抗体疗法的治疗范例 |
| IL325762A (en) | 2023-07-13 | 2026-03-01 | Christian Albrechts Universit?T Zu Kiel | Human anti-CD7 antibody |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11852A (en) | 1854-10-31 | Abraham bassford | ||
| US106A (en) | 1915-08-24 | Specipication | ||
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| PL195870B1 (pl) * | 1998-08-11 | 2007-11-30 | Biogen Idec Inc | Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny |
| EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US20020058029A1 (en) | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| EP2270050B1 (en) * | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-CD19 antibodies with reduced immunogenicity |
| PL2383297T3 (pl) * | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| AU2008260498B2 (en) * | 2007-05-30 | 2012-11-29 | Xencor, Inc. | Methods and compositions for inhibiting CD32b expressing cells |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| JP2012518404A (ja) | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Ｃｄ１９に結合するヒト化抗体及びその使用 |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| EP2501237A1 (en) * | 2009-11-06 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 KR KR1020197022418A patent/KR102117202B1/ko active Active
- 2012-08-14 CA CA2841738A patent/CA2841738C/en active Active
- 2012-08-14 AU AU2012296905A patent/AU2012296905B2/en active Active
- 2012-08-14 SI SI201231992T patent/SI2744826T1/sl unknown
- 2012-08-14 MX MX2013014935A patent/MX353589B/es active IP Right Grant
- 2012-08-14 SM SM20220160T patent/SMT202200160T1/it unknown
- 2012-08-14 RS RS20220314A patent/RS63121B1/sr unknown
- 2012-08-14 HU HUE12745883A patent/HUE058855T2/hu unknown
- 2012-08-14 RU RU2014103490A patent/RU2664462C9/ru active
- 2012-08-14 KR KR1020207014644A patent/KR20200060779A/ko not_active Withdrawn
- 2012-08-14 LT LTEPPCT/EP2012/065904T patent/LT2744826T/lt unknown
- 2012-08-14 EP EP22155604.6A patent/EP4083071A3/en active Pending
- 2012-08-14 WO PCT/EP2012/065904 patent/WO2013024095A1/en not_active Ceased
- 2012-08-14 US US14/127,217 patent/US20140227277A1/en not_active Abandoned
- 2012-08-14 CN CN201280036572.4A patent/CN103703027B/zh active Active
- 2012-08-14 PT PT127458834T patent/PT2744826T/pt unknown
- 2012-08-14 PL PL12745883T patent/PL2744826T3/pl unknown
- 2012-08-14 JP JP2014525432A patent/JP6114273B2/ja active Active
- 2012-08-14 KR KR1020147006942A patent/KR20140071368A/ko not_active Ceased
- 2012-08-14 SG SG10201606788VA patent/SG10201606788VA/en unknown
- 2012-08-14 BR BR112013033916-0A patent/BR112013033916B1/pt active IP Right Grant
- 2012-08-14 ES ES12745883T patent/ES2909720T3/es active Active
- 2012-08-14 HR HRP20220224TT patent/HRP20220224T1/hr unknown
- 2012-08-14 DK DK12745883.4T patent/DK2744826T3/da active
- 2012-08-14 EP EP12745883.4A patent/EP2744826B1/en active Active
-
2014
- 2014-01-02 IL IL230295A patent/IL230295B/en active IP Right Grant
- 2014-03-12 ZA ZA2014/01835A patent/ZA201401835B/en unknown
-
2020
- 2020-04-03 US US16/839,903 patent/US20200352975A1/en not_active Abandoned
-
2022
- 2022-04-14 CY CY20221100284T patent/CY1125148T1/el unknown
-
2024
- 2024-02-20 US US18/581,959 patent/US20240424012A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288203A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| LT2744826T (lt) | Kombinuota terapija su anti-cd19 antikūnu ir purino analogu | |
| DK2917790T3 (da) | Horologe med opbevaret og interchangeable face | |
| DK3045187T3 (da) | Injektor og fremgangsmåde til samling | |
| LT2794654T (lt) | Anti-phf-tau antikūnai ir jų panaudojimas | |
| DK2785375T3 (da) | Anti-pd-l1-antistoffer og anvendelser deraf | |
| DK2723869T3 (da) | Il-15 og il-15r alpha-sushi-domænebaseret immunocytokiner | |
| DK3262932T3 (da) | Genmodificerede mus med major histokompatibilitetskompleks | |
| BR112014000238A2 (pt) | método e artigo | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| DK2914633T3 (da) | Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| IL223147B (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| DK2744515T3 (da) | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep | |
| SG10201604104PA (en) | Antibody formulations and methods | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| CO6870003A2 (es) | Vacunas bovinas y métodos | |
| EP2783258A4 (en) | TONER AND DEVELOPER | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| DK2739748T3 (da) | Il22ra2-gen med fibrosefølsomhed og anvendelser deraf | |
| PL2678714T3 (pl) | Dozymetr zdarzeń i powiązane sposoby |